FDA recap: First new treatment for stroke in 3 decades, generic rivaroxaban and more

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug for the management of a rare lipid disease.In addition, semaglutide (Ozempic,

The article from Healio discusses several key updates in cardiology from the FDA. Firstly, the FDA approved tenecteplase (TNKase) for the treatment of acute ischemic stroke, marking the first new treatment for this condition in over three decades. This approval expands the use of tenecteplase, which was previously only approved for acute myocardial infarction. Additionally, the FDA has approved a generic version of the anticoagulant rivaroxaban (Xarelto), which is expected to increase access to this medication for preventing and treating blood clots. The article also touches on other FDA actions, including the approval of a new drug for heart failure with preserved ejection fraction, and updates on labeling changes for existing cardiovascular drugs. These developments signify significant advancements in the management of cardiovascular diseases, offering new treatment options and potentially more affordable alternatives.

Read the Full Healio Article at:
https://www.healio.com/news/cardiology/20250327/fda-recap-first-new-treatment-for-stroke-in-3-decades-generic-rivaroxaban-and-more

Similar Top and Current Publications

on: Thu, Feb 20th 2025
by: manilatimes

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

YORVIPATHÂ® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE,